Oncology News and Research

RSS

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.

Celldex second quarter net loss increases to $10.2 million

Celldex Therapeutics, Inc. today reported financial results for the second quarter ended June 30, 2011. Celldex reported a net loss of $10.2 million, or $0.27 per share, for the second quarter of 2011 compared to a net loss of $9.5 million, or $0.30 per share, for the second quarter of 2010.

3 Aug 2011

Incyte announces FDA acceptance of NDA filing for ruxolitinib to treat myelofibrosis

Incyte Corporation announced today that the US Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for Incyte's lead investigational compound, ruxolitinib, as a potential treatment for patients with myelofibrosis.

3 Aug 2011

Zalicus second quarter revenue decreases to $1.8 million

Zalicus Inc. today reported financial results for the second quarter ended June 30, 2011.

3 Aug 2011

Chromogenic in situ hybridization can identify ALK rearrangement in lung cancer patients

A relatively simple and inexpensive method may be used to determine whether a lung cancer patient is a candidate for crizotinib therapy, according to research published in the August issue of the Journal of Thoracic Oncology, the official monthly journal of the International Association for the Study of Lung Cancer.

3 Aug 2011

Positive results from combination drug trial for late-stage ovarian cancer

An experimental two-drug combination for treating late-stage ovarian cancer continues to produce strong results, leading its Indiana University researchers to actively pursue the next step, conducting a larger clinical trial to test the therapy and to see how it compares with existing treatments for ovarian cancer.

3 Aug 2011

Alcohol, tobacco use increase risk of upper aero-digestive tract cancers

Upper aero-digestive tract cancers (UADT), especially those of the oral cavity, pharynx, and larynx, are often referred to as alcohol-related cancers as it has been shown repeatedly that heavy drinkers, in particular, are at increased risk.

3 Aug 2011

Combination of six common QA measures could prevent radiotherapy errors

A combination of several well-known safety procedures could greatly reduce patient-harming errors in the use of radiation to treat cancer, according to a new study led by Johns Hopkins researchers.

3 Aug 2011

JVIR's impact factor increases nearly 15% during 2010

The Journal of Vascular and Interventional Radiology's impact factor—the measure of a journal's "impact" based on the number of article citations compared to the total number of articles published—increased nearly 15 percent in 2010.

3 Aug 2011

USPTO issues notice of allowance for Vermillion's PAD biomarker patent

Vermillion, Inc., a molecular diagnostics company, today announced that the United States Patent and Trademark Office has issued a notice of allowance for a patent entitled "Beta-2 microglobulin as a Biomarker for Peripheral Artery Disease."

3 Aug 2011

BioSante closes underwritten public offering of common stock

BioSante Pharmaceuticals, Inc. today announced the closing of its underwritten public offering of 16.0 million shares of common stock at a public offering price of $3.00 per share, for total gross proceeds of $48.0 million before underwriting discounts and commissions.

3 Aug 2011

Lipid nanocarriers in cancer diagnosis and therapy: New book

This book introduces fundamental principles of lipid nanocarriers science relevant to cancer therapy. The first in this field, it fills a need for an accurate, coherent and authoritative introduction to lipid nanocarriers focusing in cancer therapy; both because of the growing popularity of these modern drug delivery systems and also because of the emergent need of dealing with cancer treatment.

2 Aug 2011

ARIAD reports $47.8 million net loss for second quarter 2011

ARIAD Pharmaceuticals, Inc. today reported financial results for the second quarter and six months ended June 30, 2010 and provided an update on corporate developments.

2 Aug 2011

Rigel reports net loss of $21.5 million for second quarter 2011

Rigel Pharmaceuticals, Inc. today reported financial results for the second quarter and six months ended June 30, 2011.

2 Aug 2011

Compugen second quarter net income increases to $1.2 million

Compugen Ltd. today reported its results for the second quarter ending June 30, 2011.

2 Aug 2011

New investment to strengthen Clearbridge Accelerator's incubation platform

Clearbridge Accelerator announced today that it has received an investment from Tim Draper, a well-established venture capitalist based in the Silicon Valley.

2 Aug 2011

AstraZeneca recruits patients for KODIAC Phase III trial in opioid-induced constipation

AstraZeneca today announced that study centers across the U.S. are recruiting patients for a clinical study to examine whether an investigational drug is safe and effective in treating opioid-induced constipation.

2 Aug 2011

Positive results from Jennerex JX-594 proof-of-concept trial on metastatic melanoma

Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic products for cancer, today announced that positive results from a proof-of-concept clinical trial using JX-594 to treat patients with metastatic melanoma were published in the peer-reviewed journal Molecular Therapy.

2 Aug 2011

Merrimack receives FDA orphan drug status for MM-398 to treat pancreatic cancer

Merrimack Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted MM-398 orphan drug status for the treatment of pancreatic cancer.

2 Aug 2011

Alnylam second quarter revenue decreases to $20.6 million

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today reported its consolidated financial results for the second quarter 2011, and company highlights.

From Precision NanoSystems Inc. 2 Aug 2011

Femta files IND with FDA for FM101 monoclonal antibody against RA

Femta Pharmaceuticals announced today that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) to initiate a clinical development program for FM101, a high-affinity, humanized monoclonal antibody against Interleukin-6 (IL-6), in patients with rheumatoid arthritis (RA).

1 Aug 2011